Fixed‐dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block

(2019) Vasilios G. Athyros et al.   Current Vascular Pharmacology

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

(2019) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections

(2018) René Rodriguez-Gutierrez et al.   ANNALS OF INTERNAL MEDICINE

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial

(2018) Ryuzo Kawamori et al.   DIABETES OBESITY & METABOLISM

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

(2018) Hussein Al Jobori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial

(2018) Kohei Kaku et al.   DIABETES OBESITY & METABOLISM

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

(2018) Julio Rosenstock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

(2016) Eirik Søfteland et al.   DIABETES CARE

Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials

(2016) Francisco J. Tinahones et al.   DIABETES OBESITY & METABOLISM

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

(2016) André J. Scheen   Expert Opinion on Drug Metabolism & Toxicology

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

(2015) Andrew Lewin et al.   DIABETES CARE

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

(2015) Ralph A. DeFronzo et al.   DIABETES CARE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Achievement of Goals in U.S. Diabetes Care, 1999–2010

(2013) Mohammed K. Ali et al.   NEW ENGLAND JOURNAL OF MEDICINE

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

(2011) Valerie Hutchins et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM